High-dose cyclophosphamide with autologous marrow transplantation for small cell carcinoma of the bronchus

1983 ◽  
Vol 10 (3) ◽  
Author(s):  
RobertL. Souhami ◽  
PeterG. Harper ◽  
David Linch ◽  
Colin Trask ◽  
AnthonyH. Goldstone ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Marrow Transplantation ◽  
Small Cell ◽  
High Dose

High-dose cyclophosphamide with autologous marrow transplantation as initial treatment of small cell carcinoma of the bronchus

1982 ◽  
Vol 8 (1) ◽  
pp. 31-34 ◽  
Author(s):  
R. L. Souhami ◽  
P. G. Harper ◽  
D. Linch ◽  
C. Trask ◽  
A. H. Goldstone ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Marrow Transplantation ◽  
Initial Treatment ◽  
Small Cell ◽  
High Dose

Effect of high-dose chemotherapy with autologous stem cell rescue (HDC-aSCR) on outcome in ovarian small-cell carcinoma, hypercalcemic type (SCCOHT): Prospective series from the French Rare Gynecologic Malignant Tumors Network (TMRG).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. 6023-6023 ◽  
Author(s):  
Felix Blanc ◽  
Claudia Lefeuvre ◽  
Anne Floquet ◽  
Dan Chaltiel ◽  
Isabelle Laure Ray-Coquard ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Performance Status ◽  
Diagnostic Delay ◽  
Small Cell ◽  
High Dose ◽  
Rapid Progression ◽  
Pelvic Radiotherapy ◽  
Event Free Survival ◽  
Free Survival

6023 Background: Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a rare and rapidly lethal disease affecting young women with over half dying within 2 years of diagnosis. We previously reported improved outcomes with cytoreductive surgery followed by HDC-aSCR in a prospective study, but these encouraging results needed to be confirmed in an independent and larger cohort. Methods: Between 2008 and 2019, out of 44 patients (pts) diagnosed with centrally confirmed SCCOHT in 16 referent centers of the TMRG network, 38 were treated prospectively according to the French recommendations of the network with complete surgery (primary or after neoadjuvant chemotherapy), 4 to 6 cycles of PAVEP chemotherapy (cisplatin, doxorubicin, vepeside, and cyclophosphamide), and for pts with complete response (CR), HDC-aSCR, followed by pelvic radiotherapy. The 6 patients who could not receive PAVEP (unfit or diagnostic delay) relapsed and died rapidly. The primary endpoint was the event-free survival (EFS) in the intention-to-treat cohort. Results: Median age at diagnosis was 33 years (14-76). 13 pts presented with FIGO stage I, 17 stage III and 6 stage IV, 2 unknown. Median follow-up was 55.5 months. 34 patients achieved CR with CT + surgery and 30 received HDC-aSCR (40%, 47% and 10% with stages I, III and IV diseases respectively) and 21 received also pelvic radiotherapy. Median overall and event-free survival was 36.4 and 15.9 months respectively, and 2-years event-free survival rate was 40% (CI95% 25-56). Median OS was respectively not reached, 18 and 9.6 months for FIGO I, III and IV patients. Among the pts (N = 14) who did not receive HDC-aSCR (rapid progression during or after PAVEP), the 2-yr EFS was 0% compared to 50.5% for the 30 patients receiving HDC. In multivariate analysis, HDC was significantly correlated with better outcomes (p < 0.001). For the 21 patients receiving also pelvic radiotherapy, 57% (12/21) are free of recurrence at 4 years. Grades 3/4 adverse events were frequent (78%) but, in most cases, manageable, although one toxic death (3%) occurred during HDC (fungal septic shock). Conclusions: Treatment of SCCOHT, with intensive multimodal therapy, is associated with a 40% 2-yr event-free survival. However, this protocol is associated with significant toxicity and should be restricted to good performance status patient and expert centers.

High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lung

Cancer ◽  
1983 ◽  
Vol 52 (10) ◽  
pp. 1778-1782 ◽  
Author(s):  
Martin Brower ◽  
Desmond N. Carney ◽  
Daniel C. Ihde ◽  
Joyce Eddy ◽  
Paul A. Bunn ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
High Dose ◽  
High Dose Methotrexate ◽  
Dose Methotrexate ◽  
Leucovorin Rescue

scholarly journals The treatment of small cell carcinoma of the ovary hypercalcemic type

2011 ◽  
pp. 61-66 ◽  
Author(s):  
Joseph Gerald Pressey
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
High Dose Chemotherapy ◽  
Small Cell ◽  
High Dose ◽  
Cell Of Origin ◽  
Treatment Regimens ◽  
Stem Cell Rescue ◽  
Multiagent Chemotherapy ◽  
Carcinoma Of The Ovary

Small cell carcinoma of the ovary hypercalcemic type (SCCOHT) is an exceedingly rare and poorly characterized tumor with an unknown cell of origin. SCCOHT typically occurs in adolescents and young women with a peak incidence in the third decade of life. The initial description of SCCOHT noted a dismal outcome among patients, particularly those with advanced disease. However, recently published studies indicate that SCCOHT is often amenable to therapy and even in advanced stages potentially curable. Surgery paired with multiagent chemotherapy including platinum-based agents and etoposide are often cited in patients who achieve a complete remission. While reports of successfully treated patients have emerged, the scarcity of prospective clinical trials has slowed the validation of effective treatment regimens. The value of extensive surgery, radiation therapy, and high-dose chemotherapy with autologous stem cell rescue remain uncertain. Insight into the biology underlying SCCOHT is desperately needed to guide the implementation of novel therapeutics in SCCOHT.

scholarly journals Small cell carcinoma of the prostate after high-dose-rate brachytherapy for low-risk prostatic adenocarcinoma

2012 ◽  
Vol 5 (1) ◽  
pp. 53-56 ◽  
Author(s):  
AKIRA KOMIYA ◽  
KENJI YASUDA ◽  
TETSUO NOZAKI ◽  
YASUYOSHI FUJIUCHI ◽  
SHIN-ICHI HAYASHI ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Dose Rate ◽  
Small Cell Carcinoma ◽  
High Dose Rate ◽  
Small Cell ◽  
Prostatic Adenocarcinoma ◽  
Low Risk ◽  
High Dose ◽  
High Dose Rate Brachytherapy ◽  
Carcinoma Of The Prostate

scholarly journals Increased survival with high-dose multifield radiotherapy and intensive chemotherapy in limited small cell carcinoma of the lung

Cancer ◽  
1985 ◽  
Vol 56 (12) ◽  
pp. 2771-2778 ◽  
Author(s):  
Brenda Shank ◽  
Howard Scher ◽  
Basil S. Hilaris ◽  
Carl Pinsky ◽  
Michelle Martin ◽  
...  
Keyword(s):  
Cell Carcinoma ◽  
Small Cell Carcinoma ◽  
Small Cell ◽  
High Dose ◽  
Intensive Chemotherapy
Sign in / Sign up

Export Citation Format

Share Document